In high-shear and fluid-bed wet granulation trains processing thermolabile actives, AmyloTab™ C is introduced as an aqueous binder dispersion at a concentration governed by granule endpoint torque and final tablet hardness. The dispersion is prepared at 5–15% w/w solids in deionized water at 25–35 °C; because the starch is pregelatinized, no jet-cooking stage is required and viscosity develops within 15–30 min under low-torque propeller agitation. On production-scale high-shear mixers such as a Diosna P250 or Collette Gral 600, binder addition at 2–6% w/w of dry powder mass is paired with impeller power-draw monitoring; the endpoint is accepted when the wet mass achieves a defined torque threshold and the loss-on-drying after subsequent fluid-bed drying is 1–2% w/w. Fluid-bed drying in a Glatt GPCG 120 with inlet air temperature 60–70 °C and product temperature 35–40 °C must be terminated before overdrying because particle friability increases and downstream tablet friability under USP <1216> can exceed 1.0%. Granules produced with AmyloTab™ C at the lower binder level yield tablets that disintegrate within 15 min under USP <701>, provided that tablet compression force is adjusted to keep crushing strength in the 80–120 N range for immediate-release coating. Batch-to-batch variance in granule size distribution is most readily controlled by pre-blending the starch with the active and diluent prior to binder spray; direct addition of the starch into the binder vessel without sieving can generate fish-eye aggregates that transfer into the dryer and produce oversized granules. The torque endpoint must be benchmarked against placebo and active batches because compendial granulation tests do not define process endpoint.

Direct Compression Line Losses Trace to Feed-Shoe Segregation

The principal constraint in direct compression is not intrinsic compressibility but the segregation tendency of low-density binder particles at rotary press feed-shoe speeds above 60 rpm. AmyloTab™ C, used as a dry filler-binder at 10–30% w/w, shifts the blend’s bulk density and cohesivity such that die-fill weight CV remains below 1.0% on a Korsch XL 400 or Fette 3200i, provided that a glidant such as colloidal silicon dioxide at 0.5–1.0% w/w is pre-mixed. Powder flow is characterized by USP <1174> angle-of-repose and ring-shear flow function coefficient measured under 3 kPa preconsolidation; blends containing unmodified pregelatinized starch at the upper range typically produce an angle of repose near 35–40°, which is acceptable for force-fed presses but marginal for gravity-fed hoppers. The low equilibrium moisture of AmyloTab™ C relative to microcrystalline cellulose supports direct compression of moisture-sensitive actives; tablets compressed on an instrumented press at 150–250 MPa compression pressure show friability below 0.5% when tested by USP <1216>, but excipient levels above 30% w/w can produce a measurable decline in tensile strength. Lubrication must be limited to 0.5–1.0% w/w magnesium stearate and blended for 3–5 min, because excessive shear coats the starch particles and delays aqueous ingress. A production-scale failure mode observed on rotary presses is die-fill oscillation caused by pre-sintering of starch fines in the feed shoe when the press room dew point exceeds 15 °C; this is corrected by controlling relative humidity below 60% and by adding the lubricant as the final component.

When low-dose actives are filled on dosator-type encapsulation machines, AmyloTab™ C functions as a flow-regulating and compaction-stable diluent rather than as a wet binder. On MG2 Planeta and Zanasi dosator machines operating at 50,000–100,000 capsules/h, dose weight variation under USP <905> is influenced by the plug height retained in the dosator nozzle; the pregelatinized starch component at 5–25% w/w increases powder bed cohesion sufficiently to prevent nozzle leakage without promoting rat-holing in the hopper. The equivalence between tamping-pin machines, such as Bosch GKF 1500, and dosator lines is not automatic; tamping machines require lower Carr index values below 25% for uniform pin penetration, whereas dosator machines tolerate slightly higher cohesive fractions. Capsule formulations containing AmyloTab™ C as a partial filler and disintegrant disintegrate within 10–15 min under USP <701> when the gelatin or HPMC shell opens in 2–4 min; dissolution performance is determined by the soluble fraction of the starch and the particle size of the drug, not solely by the filler. Pre-blending of the starch with a hydrophobic active for 15 min in a bin blender at 10 rpm reduces agglomerates that would otherwise cause content uniformity failures. For low-fill-weight capsules below 100 mg total fill, the starch is normally sieved through a 600 µm screen to remove oversized fraction. The compendial powder-flow chapters do not directly predict dosator plug retention, so filling trials with the target powder-bed height are required.

What Controls Disintegration Time in Orodispersible Granules?

Rapid disintegration in orodispersible granule formulations is governed less by tablet hardness than by the interstitial water uptake capacity of the filler-binder network. AmyloTab™ C at 5–12% w/w in orally disintegrating tablets based on mannitol or sorbitol provides cold-water swelling that opens the tablet matrix, while a disintegrant such as crospovidone or croscarmellose sodium at 3–5% w/w contributes shear-driven wicking. The dual mechanism is required because pregelatinized starch alone may form a viscous gel layer that temporarily retards water penetration at the tablet surface. Disintegration time under USP <701> for such formulations is typically specified at ≤30 s when tested in 900 mL of water at 37 ± 2 °C; the measurement is sensitive to prior granule porosity, so fluid-bed granulation should target a granule moisture content of 1–3% w/w and a median particle size of 120–250 µm. Granules for sachet administration are produced by spray agglomeration in a Glatt GPCG or Hüttlin unit; the starch dispersion at 5–8% w/w solids is sprayed at an atomization air pressure of 1.5–2.5 bar to prevent overwetting. Subsequent tablet compression at 60–100 N crushing strength preserves a disintegration tongue below 30 s, but raising compression force above 120 N reduces void volume and pushes disintegration beyond 60 s. Packaging in cold-form foil or HDPE bottles with desiccant is used because the pregelatinized starch fraction absorbs moisture above 40% RH and can reduce long-term disintegration performance.

When Roller Compaction Ribbon Porosity Falls Below 0.15

Roller compaction introduces a different failure mode: overcompaction of the starch-bearing feed produces hard granules that survive tableting and no longer expose sufficient surface area for aqueous ingress. AmyloTab™ C can be included at 5–20% w/w in dry-granulated formulations to restore compactibility lost during slugging or roller compaction, but only when ribbon porosity is maintained above approximately 0.15. On an Alexanderwerk WP 120 roller compactor operating with a roll gap of 2–4 mm and specific roll force of 4–12 kN/cm, the starch acts as a plastic deformation component during compaction, yet its binder efficiency after milling depends on the granule fine fraction. Milling through a 1.0 mm screen with rotor speed 100–150 rpm generates a broad size distribution; the fraction above 500 µm must be recycled to the compactor to avoid tablet weight variation under USP <905>. For a final tablet crushing strength of 70–110 N, the roller-compacted granulation often requires the addition of extragranular disintegrant at 2–4% w/w because the intragranular starch has already been compressed beyond its swelling capacity. Tablets produced from ribbon with porosity below 0.15 show disintegration times above 30 min under USP <701>, regardless of extragranular disintegrant grade, due to insufficient capillary channels. The operational boundary is therefore narrow; ribbon density should be monitored in-line, and feed-screw speed adjusted to maintain ribbon thickness variation below ±0.2 mm. Published data for this specific pregelatinized starch grade in roller compaction is limited, so feasibility batches should compare ribbon porosity at three specific roll forces.

For terminal-sterilized aqueous suspensions and lyophilized parenteral formulations, the low-endotoxin grade of AmyloTab™ C is evaluated against USP <788> particulate matter limits and route-specific bacterial endotoxin thresholds rather than oral formulation performance. Because pregelatinized starch is a high-molecular-weight polysaccharide of botanical origin, injectable formulation is confined to niche applications such as depot suspension vehicles, lyophilized cake structuring, or organoleptic masking in oral liquids that require low bioburden stock. In lyophilized vials, addition of 1–5% w/w pregelatinized starch is screened for cake appearance and reconstitution time using a freeze-dryer with shelf temperature ramp from -45 °C to 25 °C over 24–48 h; residual moisture is measured by USP <921> and maintained below 1.5%. The viscosity of a pregelatinized starch dispersion at 2% w/w in water is sufficient to retard settling of suspended active in a non-Newtonian gel-like vehicle, but the dispersion is not a true solution and cannot pass a 0.22 µm sterilizing filter; terminal steam sterilization or pre-sterilization of the starch by gamma irradiation is required. Particle size distribution of the hydrated starch in suspension is measured by laser diffraction according to ISO 13320:2020; particles above 10 µm require justification under USP <788> large-volume parenteral limits. Sterility assurance is confirmed by USP <71>, endotoxin by USP <85>, and injectable-grade excipient release must meet phosphate buffered saline compatibility, absence of pyrogens, and controlled swelling volume. Published data for this specific injectable configuration is limited, and most commercial parenteral products rely on chemically modified starches rather than unmodified pregelatinized starch.